Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

CTXR Citius Pharmaceuticals Inc

0,6175

-0,0142 (-2,25%)

08 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form ARS - Annual Report to Security Holders

Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Citius Pharmaceuticals Charts.

Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Citius Pharmaceuticals Charts.

News Citius Pharmaceuticals Inc

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Mittwoch 29 Mai 2024 (1 Woche vor) • PR Newswire (US)

Form 8-K - Current report
Dienstag 21 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Dienstag 21 Mai 2024 (3 Wochen vor) • PR Newswire (US)

Form 8-K - Current report
Dienstag 14 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 14 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
Dienstag 14 Mai 2024 (4 Wochen vor) • PR Newswire (US)

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
Freitag 10 Mai 2024 (4 Wochen vor) • PR Newswire (US)

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
Dienstag 30 April 2024 (1 Monat vor) • PR Newswire (US)

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
Freitag 26 April 2024 (1 Monat vor) • PR Newswire (US)

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Donnerstag 11 April 2024 (2 Monate vor) • PR Newswire (US)

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
Donnerstag 4 April 2024 (2 Monate vor) • PR Newswire (US)

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Montag 18 März 2024 (3 Monate vor) • PR Newswire (US)

Weitere Citius Pharmaceuticals Inc News-Artikel

Euro vs US Dollar

Deutsche Telekom (QX)

Deutsche Telekom

Energy Select Sector SPDR

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen